ranked for M&A Advisory (Buy-Side)
Know when to call Eli Lilly and Company — before your competition does. kelvy agents monitor events in real time and surface ranked opportunities for Finance & Investment Banking firms.
Eli Lilly Prepares Women’s Health Expansion Funded by GLP-1 Revenue
Eli Lilly is laying the groundwork for a broader push into women’s health, assembling experts and hunting for new medicines across conditions including bone health and endometriosis, according to people familiar with the matter. The initiative is tied to funding from the company’s GLP-1 windfall, though specific medicines, deals, or timelines were not disclosed.
Highlighted Opportunity
Target Search / Origination
Lilly must map bone health and endometriosis assets before deploying GLP-1 proceeds
Lilly is entering a new therapeutic area and is already hunting for assets, creating an immediate need for proprietary deal flow in women’s health.
Track company & unlock full analysisEli Lilly to acquire psychedelic company for $360 million
Eli Lilly has agreed to acquire a psychedelic drug developer from a billionaire founder in a deal valued at $360 million. The transaction involves the sale of the entire company, with the founder receiving the full proceeds.
Highlighted Opportunity
Target Search / Origination
Lilly must build a proprietary pipeline of psychedelic assets to sustain its new vertical
Entering the psychedelic therapeutics vertical creates a need to source and vet additional proprietary targets; without a systematic origination process, Lilly risks ad-hoc pric...
Track company & unlock full analysisWe'll prefill M&A Advisory (Buy-Side) and this company so you land in a personal feed of ranked opportunities — not a blank account.
Public preview. Create an account to personalize scoring and digests.